333. Hutchinson-Gilford syndrome Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 8 / Drugs : 8 - (DrugBank : 3) / Drug target genes : 4 - Drug target pathways : 6
Drugs and their primary sponsors and trial info
Lonafarnib
Boston Children's Hospital
2009 Phase 2 NCT00879034 United States;
Eiger BioPharmaceuticals
2020 - NCT03895528 -
Monica E. Kleinman
2007 Phase 2 NCT00425607 United States;
Lonafarnib, Zoledronic Acid, and Pravastatin
Boston Children's Hospital
2009 Phase 2 NCT00916747 United States;
Pravastatin
Boston Children's Hospital
2009 Phase 2 NCT00879034 United States;
Progerinin
PRG Science & Technology Co., Ltd.
2020 Phase 1 NCT04512963 United States;
Umbilical Cord Blood Unit
Bundang CHA Hospital
2019 Phase 1/Phase 2 NCT03871972 Korea, Republic of;
Zoledronic acid, pravastatin
Assistance Publique Hopitaux De Marseille
2008 Phase 2 NCT00731016 France;
Boston Children's Hospital
2009 Phase 2 NCT00879034 United States;
Eiger BioPharmaceuticals
2020 - NCT03895528 -
Monica E. Kleinman
2007 Phase 2 NCT00425607 United States;
Lonafarnib, Zoledronic Acid, and Pravastatin
Boston Children's Hospital
2009 Phase 2 NCT00916747 United States;
Pravastatin
Boston Children's Hospital
2009 Phase 2 NCT00879034 United States;
Progerinin
PRG Science & Technology Co., Ltd.
2020 Phase 1 NCT04512963 United States;
Umbilical Cord Blood Unit
Bundang CHA Hospital
2019 Phase 1/Phase 2 NCT03871972 Korea, Republic of;
Zoledronic acid, pravastatin
Assistance Publique Hopitaux De Marseille
2008 Phase 2 NCT00731016 France;